Compares zanzalintinib with everolimus in people with advanced neuroendocrine tumors
Tests zanzalintinib against everolimus in adults with previously treated neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Key facts
- Where
- London, Ottawa, and Toronto, CanadaSee the 3 sites
- Phase
- Phase 2/3
Where in Canada
- Verspeeten Family Cancer Center - London Health Sciences CentreLondon, CanadaTaking people
- The Ottawa Hospital Cancer CenterOttawa, CanadaTaking people
- Sunnybrook Health Sciences CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Exelixis
- Trial code
- NCT06943755EU 2025-521043-20-00
- Record updated
- 30 October 2026
- Original description
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.Read full original descriptionShow less
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Inclusion: Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin; Allowed prior lines of therapy, based on the site of NET and functional status; Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization; Measurable disease according to RECIST 1.1 as determined by the Investigator; Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue.
Exclusion: Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor; Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization; Systemic radionuclide therapy within 6 weeks before randomization; Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization; Note: Other protocol defined Inclusion/Exclusion criteria may apply; Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN).